drugset / Trial / NCT01995526

A Study of Insulin Peglispro in Healthy Male Japanese Participants

NCT01995526

Phase 1 Completed 11 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate how the body processes the study drug known as insulin peglispro and how the study drug affects blood sugar in healthy male Japanese participants. This study will also evaluate safety of the study drug. The study will last up to 46 days for each participant, not including screening.

Timeline

Start
2013-12
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Peglispro Protein / enzyme biologic 1.3 iu/kg Subcutaneous

Indications

No indication recorded.